Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

NCT00026312 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1449

Enrollment

NIH

Sponsor class

Conditions

Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
Stage 4S Neuroblastoma

Interventions

BIOLOGICAL: Aldesleukin
BIOLOGICAL: Dinutuximab
DRUG: Isotretinoin
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
OTHER: Quality-of-Life Assessment
BIOLOGICAL: Sargramostim

Sponsor

National Cancer Institute (NCI)